# Benjamin Solomon

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/benjamin-solomon/

## Facts

| Field | Value |
| --- | --- |
| Citations | 65,505 |
| Field | Lung Cancer Treatments and Mutations |
| h-index | 100 |
| i10-index | 345 |
| Last Known Institution | The University of Melbourne |
| OpenAlex ID | https://openalex.org/A5045959942 |
| ORCID iD | 0000-0003-3059-5730 |
| Works | 814 |

## Researcher papers

Showing 12 of 31.

- [Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer](https://scholariq.org/papers/anaplastic-lymphoma-kinase-inhibition-in-non-small-cell-lung-cancer/)
- [Crizotinib versus Chemotherapy in Advanced <i>ALK</i> -Positive Lung Cancer](https://scholariq.org/papers/crizotinib-versus-chemotherapy-in-advanced-i-alk-i-positive-lung-cancer/)
- [First-Line Crizotinib versus Chemotherapy in <i>ALK</i>-Positive Lung Cancer](https://scholariq.org/papers/first-line-crizotinib-versus-chemotherapy-in-i-alk-i-positive-lung-cancer/)
- [Lung cancer](https://scholariq.org/papers/lung-cancer-2/)
- [Comprehensive genomic profiles of small cell lung cancer](https://scholariq.org/papers/comprehensive-genomic-profiles-of-small-cell-lung-cancer/)
- [Crizotinib in <i>ROS1</i>-Rearranged Non–Small-Cell Lung Cancer](https://scholariq.org/papers/crizotinib-in-i-ros1-i-rearranged-non-small-cell-lung-cancer/)
- [Clinical Features and Outcome of Patients With Non–Small-Cell Lung Cancer Who Harbor <i>EML4-ALK</i>](https://scholariq.org/papers/clinical-features-and-outcome-of-patients-with-non-small-cell-lung-cancer-who/)
- [Ceritinib in <i>ALK</i> -Rearranged Non–Small-Cell Lung Cancer](https://scholariq.org/papers/ceritinib-in-i-alk-i-rearranged-non-small-cell-lung-cancer/)
- [Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer](https://scholariq.org/papers/integrative-genome-analyses-identify-key-somatic-driver-mutations-of-small-cell/)
- [Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry](https://scholariq.org/papers/immune-checkpoint-inhibitors-for-patients-with-advanced-lung-cancer-and/)
- [Mechanisms of Acquired Crizotinib Resistance in ALK-Rearranged Lung Cancers](https://scholariq.org/papers/mechanisms-of-acquired-crizotinib-resistance-in-alk-rearranged-lung-cancers/)
- [Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study](https://scholariq.org/papers/activity-and-safety-of-crizotinib-in-patients-with-alk-positive-non-small-cell/)

## Researcher topics

- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Lung Cancer Research Studies](https://scholariq.org/topics/lung-cancer-research-studies/)
- [Lung Cancer Diagnosis and Treatment](https://scholariq.org/topics/lung-cancer-diagnosis-and-treatment/)
- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [Colorectal Cancer Treatments and Studies](https://scholariq.org/topics/colorectal-cancer-treatments-and-studies/)

## Researcher university

- [The University of Melbourne](https://scholariq.org/institutions/the-university-of-melbourne/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.